Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EbolaVac

Financiado

Cerrado

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (... ver más

06/04/2018

GSKBIO

22M€

Presupuesto del proyecto: 22M€

Líder del proyecto

GLAXOSMITHKLINE BIOLOGICALS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-04-06

DIGITAL-2024-CLOUD-AI-06-HEALTHRECORD: Demonstrating the in-service use of... Expected Outcome:Deliverables

I+D

Cerrada hace 8 meses

0% 69% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

GSKBIO

14.10M€ | Lider

BNI

107.50K€ | Participante

CHUV

1.42M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EBO-PEP The EBO-PEP project : EBOla Zaïre Post-Exposure Prophylaxis,... 3M€ Cerrado

FILOVAX Development of Broadly Protective Filovirus Vaccines 50M€ Cerrado

PEVIA PAN EBOLA VACCINE INNOVATIVE APPROACH Sofia ref. 116088 18M€ Cerrado

EbolaMoDRAD Ebola Virus Modern Approaches for developing bedside Rapid... 4M€ Cerrado

BES-2017-082074 EVOLUCION DEL VIRUS INFLUENZA PORCINA ASOCIADA A LA VACUNACI... 93K€ Cerrado

EBOVAC3 Bringing a prophylactic Ebola vaccine to licensure 51M€ Cerrado

Duración del proyecto: 39 meses Fecha Inicio: 2014-12-09
Fecha Fin: 2018-04-06

Líder del proyecto

GLAXOSMITHKLINE BIOLOGICALS SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 22M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and estimates the true number of cases at 2.5 times higher than that reported. Countries that have been affected are Guinea, Liberia, Nigeria, Senegal and Sierra Leone. Ten percent of fatalities have occurred among front line health care workers attempting to contain the epidemic. On 7 August 2014, the WHO requested that GSK fully engage in WHO-coordinated efforts to test, license and make available safe and effective Ebola interventions to assist in the control of the outbreak. Taking into account the early stage of development, EbolaVac seeks to accelerate the clinical development of the GSK chimpanzee adenovirus type 3 Ebolavirus Zaire (ChAd3-EBO Z) vaccine candidate to make the vaccine available to frontline health care workers at risk and to be used in the containment of EBOV outbreaks. The project specifically aims to: (i) complete Phase 1 development of the ChAd3-EBO Z vaccine by supporting a clinical study conducted in Lausanne, Switzerland (WP2); (ii) evaluate the ChAd3-EBO Z vaccine in Phase 2 testing on adults and children at established clinical study centers in West Africa outside the current most heavily affected countries of Guinea, Sierra Leone, and Liberia (WP3); (iii) investigate immunological effects of vaccination and the effect of booster vaccination (WP4) and (iv) centrally manage and analyse clinical study data (WP5). Besides using an innovative vaccine technology, much of the innovation of this program will reside in its capacity to implement vaccine evaluation under significant time pressure and complex logistical challenges while maintaining appropriate quality standards.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores